Stock market strife subsides in second quarter
But large gains for some big pharma players flatter the overall figures.
More, but slower, medtech approvals
If the second half maintains the pace, 2023 could see the most device approvals for a decade.
Venture financing ticks up for biopharma
But, with an ever-growing proportion of the cash going to a select few, the gulf between the haves and the have-nots is widening.
Biopharma's flotation haul creeps higher
Life is returning to the IPO scene, but the recovery is slow and uncertain.
Medtech dealmaking grinds almost to a halt
M&A moves are down, venture rounds few and IPOs nonexistent.
Biopharma buyouts bounce back
Developers brush off antitrust scrutiny and drug price curbs and succumb to the urge to merge.
UCB leads the stale scale
Several big groups’ portfolios are ageing, and regulatory action risks blocking their renewal.
Unpartnered assets: on the shelf or hidden treasure?
A look at biopharma’s most highly valued yet unpartnered assets features Karuna, Ventyx and regular bridesmaid Ascendis.